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Background: It is seen that the regioselective functionalizations of halogenated heterocycles play an important role
in the synthesis of several types of organic compounds. In this domain, the Suzuki-Miyaura reaction has emerged as
a convenient way to build carbon-carbon bonds in synthesizing organic compounds. Some of the most important
applications of these reactions can be seen in the synthesis of natural products, and in designing targeted pharmaceutical
compounds. Herein, we present the regioselective synthesis of the novel series of 2-(bromomethyl)-5-aryl-thiophenes 3a-i,
via Suzuki cross-coupling reactions of various aryl boronic acids with 2-bromo-5-(bromomethyl)thiophene (2).
Results: The synthesized compounds were screened for their haemolytic and antithrombolytic activities. The novel
compounds 3f, 3i showed highest 69.7, 33.6% haemolysis of blood cells, respectively. The antithrombolytic activity of
the compounds was found to be within low to moderate against human blood clot. The compound 3i showed potent
clot lysis (31.5%).
Conclusions: Considering these results, it is concluded that the synthesized compounds can be used as a promising
source of therapeutic agents.
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In present days, the synthesis of new and safe thera-
peutic agents is getting high importance in the field of
medicinal science and pharmaceuticals. Most precisely,
sulphur containing heterocycles are seen as the center of
activity due to their widespread use in several important
medicinal compounds. However, it is seen that the suc-
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Substituted thiophene derivatives are well known for their
chemotherapeutic applications. Many thiophene based
heterocyclic compounds have shown versatile pharmaco-
logical activities such as antimicrobial [1,2], antiamoebic
[3], antiparasitic, anticancer [4], antifolates, antipsychotic
[5], diabetes mellitus [6], anticonvulsant [7], analgesic [8],
antidepressant [9], antihistaminic, anticholinergic [10],
antiallergic [11]. In addition, the cholesterol inhibition ac-
tivity and as antagonist against many hormones releasing
receptors has also been reported. In a yet different con-
text, the thiophene based heterocyclic compounds has
also been employed in formulizing computer printer’s ink
and as a raw material for herbicides and pesticides [12].s an Open Access article distributed under the terms of the Creative Commons
org/licenses/by/4.0), which permits unrestricted use, distribution, and

















Scheme 1 Synthesis of intermediate compound 2-bromo-5-
(bromomethyl)thiophene (2) and 2-(bromomethyl)-5-aryl-
thiophenes 3a–i. Conditions: i, 1, (1 eq, 20.4 mmol), NBS (2.1 eq,
42.84 mmol), CCl4 (9–10 mL). Procedure: reflux 1 and NBS in CCl4 for
4–5 hours; Condition ii, 2 (1 eq, 0.976 mmol), Pd(PPh3)4 (2.5 mol%)
aryl boronic acid (1.1 eq, 1.073 mmol), K3PO4 (2 eq, 1x.952 mmol),
1,4-dioxane/H2O (4:1) (Table 1), 12 h, 90°C.
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containing compounds constitutes an important class of
materials, which show intrinsic electronic properties such
as luminescence, redox activity, non-linear optical chro-
mism and electron transport [13-17]. The incidence of
death due to thrombosis is higher in the world. Antith-
rombolytic activity of thiophene based compounds has
been reported in literature [18,19].
In the synthesis of several types of organic compounds,
the transition metal-catalyzed reactions are well known
for the formation of new carbon–carbon (C–C) bonds.
In this context, the Pd-catalyzed Suzuki–Miyaura coup-
ling reaction [20] is one of the most efficient and unique
method for the C–C bonds formation due to the re-
quirement of mild reaction conditions, easily available
environmentally safe organoboron compounds, high tol-
erance of functional groups and easy handling of the by-
products [21-25].
The Suzuki–Miyaura cross-coupling reaction, which
produces biaryls has proven to be the most important
building blocks in organic synthesis owing to their indus-
trial applications. We have previously reported the synthesis
of arylthiophenes by regioselective Suzuki cross-coupling
reactions and they were potentially studied as pharma-
ceutical agents [26,27].
There are few reports about the Suzuki Cross Coupling
reaction of benzyl halides with different palladium cata-
lysts under variable reaction conditions. Langle et al. [28]
reported the Suzuki cross coupling reaction of unsymmet-
rical diarylmethanes, while Bandgar et al. [29] reported
ligand free Suzuki cross coupling reactions of benzylic ha-
lides with aryl boronic acid. Molander and Elia [30] de-
scribed the Suzuki-Miyaura cross-coupling Reactions of
Benzyl halides with Potassium Aryltrifluoroborates. The
cross-coupling of benzylic bromides with various aryl bo-
ronic acids have also been reported under microwave con-
ditions [31].
For the first time, the present work focuses on the
synthesis of various palladium (0) catalyzed Suzuki
cross coupled derivatives of 2-bromo-5-(bromomethyl)
thiophene, particularly with the aim to investigate their




We have investigated the Suzuki cross coupling reactions
of 2-bromo-5-(bromomethyl)thiophene (2) with various
aryl boronic acids under optimized conditions. To the best
of our knowledge, no such work on the synthesis and
biological activities of 2-(bromomethyl)-5-aryl-thiophenes
(3a–i) has been reported to date.
As outlined in the reaction scheme (1), the first step in
the synthesis of 2-(bromomethyl)-5-aryl-thiophenes (3a–i)is the preparation of intermediate compound 2-bromo-5-
(bromomethyl)thiophene (2), which was obtained in 58%
yield from the reaction between 2-methylthiophene (1)
and N-bromosuccinamide in CCl4 [32] (Scheme 1).
In the next step, the Suzuki cross coupling reaction of ap-
propriate aryl boronic acids with 2-bromo-5-(bromomethyl)
thiophene (2) was carried out that eventually led to the
corresponding 2-(bromomethyl)-5-aryl-thiophenes (3a-i) in
moderate to excellent yields (25− 76%) (Scheme 1, Table 1).
The Suzuki-Miyaura cross coupling reaction of benzyl
halide with aryl boronic acid usually follow slow oxida-
tive addition and facile reductive elimination as com-
pared to aryl halide [33,34], therefore the reaction of aryl
halide with aryl boronic acid is preferred over benzyl
halide. The structures of these newly synthesized com-
pounds were investigated from the data based on elemen-
tal analyses, Mass spectrometry, 1H-NMR and 13C-NMR
spectra.
The results revealed that the compound 2-(bromomethyl)-
5-(4 methoxyphenyl)thiophene (3b) was obtained in excel-
lent yield (76%), which could be due to the solvent
mixture (1,4-dioxane/water = 4:1), which has previously
been reported to obtain high yields [35]. Another possible
explanation is the high solubility of oxygen containing bo-
ronic acids in 1,4-dioxane, which led to the obtained high
yield of compound (3b). The coupling of intermediate
compound (2) with 3-chloro-4-fluoro phenyl boronic
acid also gave 2-(bromomethyl)-5-(3-chloro-4-fluorophenyl)




5-(3,5-dimethylphenyl)thiophene (3i) were also obtained
in relatively high yields ~ 63, 61, 63, 70% respectively.
The obtained yield of products 2-(bromomethyl)-5-(4
(methylthio)phenyl)thiophene (3f), 2-(bromomethyl)-5-
Table 1 Synthesis of 2-(bromomethyl)-5-aryl-thiophenes (3a-i)
3 Aryl/ArylBoronic acids Products Solvent/H2O (4:1) Yield %
a 3-Cl-4-F-C6H3 1,4-Dioxane 65
b 4-MeO-C6H4 1,4-Dioxane 76
c 4-Cl-C6H4 1,4-Dioxane 63
d 3,5-F2-C6H3 1,4-Dioxane 61
e 3-(MeCO)-C6H4 1,4-Dioxane 63
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tolylthiophene (3h) was fair as well (Table 1). In the
cases, where low yield of products were obtained, the
steric effects of substituents attached on aryl group of
boronic acids and some practical problems associated
with difficult chromatographic purification are suggested
to be the possible issues [36]. Ortho-substituted aryl bo-
ronic acids have lack of reactivity and cannot couple
in a good way due to steric factor. Hence, boronate
anion of boronic acid are unable to attack easily on the
substrate [36].
Biology
Measurement of potential cytotoxicity by haemolytic
activity
The cytotoxicity of the synthesized compounds viz. 2
and 3a-i was studied by examining the haemolytic activ-
ity against human red blood cells. The cytotoxicity of
blood lymphocytes, thymocytes and spleen cells of vari-
ous compounds are already known [37]. When com-
pared with the positive control triton X-100 standard,
the novel compounds 3f and 3i showed significantly
high haemolytic activity ~ 69.7 and 33.6% lysis of blood
cells respectively, which can be attributed to the pres-
ence of electron donating methyl groups. Molongi et al.
[38] reported that the anticancer activity is often en-
hanced by the presence of electron releasing groups. In
contrast, the compounds viz. 2, 3a, 3b, 3c, 3d, 3e, 3g
and 3h exhibited haemolytic activity below 10% (Table 2,
Figure 1). In view of the observed differences in the %
lysis of RBC values, it is inferred that the electron with-
drawing and electron donating nature of the substituent
groups have an influence on the haemolytic activity of
the compounds [39]. Moreover, the cytotoxicity of the
compounds viz. 3f and 3i can be optimized by makingTable 2 Cytotoxicity studies by Haemolytic activity of
synthetic compounds 2 and 3a-i
Compounds % of haemolysis
2 3.06 ± 0.03
3a 1.63 ± 0.02
3b 6.31 ± 0.07
3c 3.88 ± 0.04
3d 4.43 ± 0.05
3e 5.13 ± 0.05
3f 69.7 ± 1.23
3 g 9.87 ± 0.08
3 h 3.59 ± 0.03
3i 33.6 ± 0.87
Phosphate-buffered saline (PBS) 0.00 ± 0.00
Triton X-100 100 ± 0.58
The results are average ± S.D of triplicate experiments p < 0.05.appropriate changes in the molecular structures for the
purpose of their use as toxic compounds to control the
uncontrolled proliferation of cells [38].
Antithrombolytic activity
In the field of antithrombotic research, the compounds
that exhibit anti-aggregatory activity have received a great
deal of interest from research community. Several types of
drugs such as heparin, ticlopidine, clopidogrel, plasmino-
gen activator (t-PA), urokinase and streptokinase were ex-
plored as clot lysis agent but only few of them were found
potent for clinical purposes [40-43].
Because of high death rate due to cardio-vascular dis-
eases, the clot lysis activity is very important characteristic
of any drug [44,45]. The compounds under investiga-
tion exhibited low to moderate antithrombolytic activity
against clot development in human blood. The compound
3i showed potent clot lysis (~ 31.5%), whereas, the com-
pounds 3e and 2 showed comparatively low thrombolytic
activity (Table 3, Figure 2). The values of % clot lysis for
other compounds were found moderate. However, the
results were significant p < 0.05, when compared with
streptokinase taken as control. According to the best of
our knowledge, no relative literature is available on this
type of activity for such compound.
Experimental
General
The melting points of compounds were determined using
a Buchi melting point apparatus (B-540). High pure analyt-
ical grade reagents were used throughout all experiments
and were purchased from Sigma Aldrich Chemical Co.
(St. Louis, MO, USA) and Alfa Aesar Chemical Co.
(St. Parkridge Ward Hill, MA, USA). 1H-NMR and
13C-NMR spectra were measured in CDCl3 and CD3OD
(Bruker Aspect AM-300 instrument) at 300/75 MHz re-
spectively. The chemical shift values (δ) were given in ppm
and coupling constant was measured in Hertz (Hz). EI-MS
spectra were recorded on a JMS-HX-110 spectrometer
with a data system. Elemental analysis was carried out by
using CHNS/O analyzer (Perkin-Elmer 2400 series). For
column chromatography, silica gel (70–230 mesh) and silica
gel (230–400 mesh) were used. The reactions were moni-
tored on TLC, using Merck silica gel 60 PF254 cards. The
compounds were visualized by UV lamp (254–365 nm).
General procedure for synthesis of 2-bromo-5-
(bromomethyl)thiophene (2)
To carry out bromination of 2-methylthiophene, a
weighed amount of starting material 2-methylthiophene
(1, 1 eq, 20.4 mmol) suspended in 9–10 mL of dry
carbon tetrachloride (CCl4) was made to react with N-
bromosuccinimide (NBS) (2.1 eq, 42.84 mmol). This reac-


















Figure 1 Percentage of haemolysis of synthetic compounds 2, 3a-i.
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tetrachloride under vacuum. Later on, the synthesized
compound was purified by fractional distillation. Finally,
the spectroscopic techniques were used to characterized
the purified final product [32].
General procedure for the preparation of 2-
(bromomethyl)-5-aryl-thiophene (3a-i)
Pd(PPh3)4 (2.5 mol%) was added to 2-bromo-5-(bromomethyl)
thiophene (2, 1 eq, 0.976 mmol) under nitrogen atmos-
phere and the resulting mixture was stirred for 30 min
with the addition of 1,4-dioxane (2.5 mL). After 30 min
the aryl boronic acid (1.1 eq, 1.073 mmol), K3PO4 (2 eq,
1.952 mmol) and water (0.625 mL) were added [27]. The
whole mixture was stirred for 12 h at 90°C, and was later
removed and cooled to room temperature. After cooling
to ambient temperature, the mixture was diluted with ethyl
acetate and the organic layer was separated, dried withTable 3 Percentage efficiency of Clot lysis of synthetic
compounds 2 and 3a-i
Compounds Clot lysis %
2 2.73 ± 0.03
3a 9.76 ± 0.08
3c 12.3 ± 0.15
3b 5.29 ± 0.04
3d 3.71 ± 0.04
3e 1.96 ± 0.02
3f 8.05 ± 0.07
3 g 7.28 ± 0.06
3 h 4.37 ± 0.02
3i 31.5 ± 0.45
Water 0.43 ± 0.005
Streptokinase 87.2 ± 0.95
The results are average ± S.D of triplicate experiments p < 0.05.magnesium sulfate and the solvent was removed under
vacuum. The obtained crude residue was purified by col-
umn chromatography using ethyl-acetate and n-hexane in
(1:1) ratio to get the desired products, which were further
analyzed by using different spectroscopic techniques.
Characterization data
2-bromo-5-(bromomethyl)thiophene (2). Brown liquid;
1H-NMR (300 MHz, CDCl3 + CD3OD): δ = 6.98 (d, J =
3.6 Hz, 1H), 6.83 (d, J = 3.6 Hz, 1H), 4.68 (s, 2H-CH2).
13C-NMR (75 MHz CDCl3 + CD3OD): δ = 25.4, 108.2
128.0, 128.8, 141.5; EI/MS m/z (%:) 255.0 [M+˙]; 257.0
[M+ (Br79, Br81) 100], 259.0 [M+ (Br81, Br81) 40], [M+-Br] =
177.0; [M+-CH2Br] = 163.0; [M
+-2Br] = 125.8; [M+-Br and
CH2Br fragment] = 84.0. Anal. Calcd. for C5H4Br2S: C,
23.46; H, 23.50. Found: C, 1.60; H, 1.60%.
2-(bromomethyl)-5-(3-chloro-4-fluorophenyl)thiophene (3a).
Light yellow solid, Mp: 200-250°C; 1H-NMR (300 MHz,
CDCl3 +CD3OD): δ= 7.54 (m, 1H-aryl), 7.52 (m, 1H-aryl),
7.36 (s, 1H-thiophene), 7.28 (m, 1H-aryl), 6.77 (s, 1H-
thiophene), 4.07 (s, 2H-CH2).
13C-NMR (75 MHz CDCl3 +
CD3OD): 27.4, 116.4, 121.2, 127.0, 127.6, 127.9, 129.0,
131.2, 137.0, 139.4, 158.0; EI/MS m/z (%): 304.8 [M+˙];
306.8 [M+ (Br81,Cl35) 49]; 306.8 [M+ (Br79, Cl37) 17]; 308.8
[M+ (Br81, Cl37) 49]; [M+-F] = 287.2; [M+-Cl, F-fragments] =
253.1; [M+-CH2Br, thiophene, Cl- fragments] = 96.1. Anal.
Calcd. For C11H7BrClFS: C, 43.23; H, 2.31. Found: C, 42.22;
H, 2.40%.
2-(bromomethyl)-5-(4-methoxyphenyl)thiophene (3b).
light yellow solid,Mp: 200-250°C; 1H-NMR (300 MHz,
CDCl3 + CD3OD): δ = 7.12 (d, J = 8.4 Hz, 1H-thiophene),
6.84-6.81 (m, 4H-aryl), 6.52 (d, J = 3.6 Hz, 1H-thiophene),
3.98 (s, 2H-CH2), 2.03 (s, 3H-OMe).
13C-NMR (75 MHz
CDCl3 + CD3OD): 20.4, 27.9, 125.4, 125.9, 127.7, 127.9,
129.0, 129.9, 130.0, 131.9, 135.0, 139.1; EI/MS m/z (%):
283.0 [M+˙]; 285.0 [M+ (Br81) 49]; [M+-CH2Br, thiophene] =



























Figure 2 Antithrombolytic activity of synthetic compounds 2, 3a-i.
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50.76; H, 3.80%.
2-(bromomethyl)-5-(4-chlorophenyl)thiophene (3c). Yellow
liquid; 1H-NMR (300 MHz, CDCl3 + CD3OD): δ = 7.59
(d, J= 8.4 Hz, 2H-aryl), 7.40-7.37 (m, 2H-aryl, 1H-thiophene),
7.27 (s, 1H-thiophene), 4.70 (s, 2H-CH2).
13C-NMR (75 MHz
CDCl3 + CD3OD): 27.6, 127.5 (2C), 128.5, 129.5 (2C),
128.4, 131.6, 134.1, 136.7, 139.1; EI/MS (m/z -ion mode):
286.9 [M+˙]; 288.9 [M+ (Br81,Cl35) 49]; 288.9 [M+ (Br79,
Cl37)17]; 290.9 [M+ (Br81, Cl37) 49]; [M+-Br] = 223.0;
[M+-CH2Br] = 194.2; [M
+-CH2Br, Cl fragments] = 160.1,
[M+-CH2Br, Cl, aryl fragments] = 83.2. Anal. Calcd. For
C11H8BrClS: C, 45.94; H, 2.80. Found: C, 45.90; H, 2.70%.
2-(bromomethyl)-5-(3,5-difluorophenyl)thiophene (3d).
Dark brown gummy matter; 1H-NMR (300 MHz, CDCl3 +
CD3OD): δ = 7.42 (m, 1H-aryl), 7.22 (m, 1H-aryl), 7.12
(d, J = 2.4 Hz, 1H-thiophene) 6.55 (m, 1H-aryl), 6.51
(d, J = 3.6 Hz, 1H-thiophene), 4.51 (s, 2H-CH2).
13C-NMR
(75 MHz CDCl3 + CD3OD): 27.5, 104.0, 111.1 (2C), 127.5
(2C), 136.1, 136.9, 140.0, 165.1 (2C). EI/MS m/z (%): 288.0
[M+˙]; 290.0 [M+ (Br81) 49]; [M-F] = 270.0; [M-2 F] = 254.2;
[M-CH2Br] = 196.0; [M-CH2Br, thiophene fragments] =
113.1. Anal. Calcd. For C11H7BrF2S: C, 45.69; H, 2.44.
Found: C, 45.75; H, 2.43%.
1-(3-(5-(bromomethyl)thiophene-2-yl)phenyl)ethanone (3e).
Off white gummy matter; 1H-NMR (300 MHz, CDCl3 +
CD3OD): δ = 7.87-7.85 (m, 2H-aryl), 7.50-7.41 (m, 2H-
aryl), 6.91 (d, J = 3.6 Hz, 1H-thiophene), 6.66 (d, J =
3.6 Hz, 1H-thiophene), 4.83 (s, 2H-CH2), 2.57 (S, 3H-
COMe). 13C-NMR (75 MHz CDCl3 + CD3OD): 26.5, 27.8,
126.0, 127.5 (2C), 128.5, 129.5, 130.5, 133.4, 136.0, 137.1,
139.0, 197.4. EI/MS m/z (%): 294.1 [M+˙]; 296.0 [M+ (Br81)
49]; [M+-Me] = 281.0 [M+-COMe] = 253.0, [M+-CH2Br] =
201.1, [M+-CH2Br, aryl, COMe] = 84.0. Anal. Calcd. For
C13H11BrOS: C, 52.89; H, 3.76. Found: C, 52.80; H, 3.66%.
2-(bromomethyl)-5-(4-(methylthio)phenyl)thiophene (3f).
off white solid,Mp: 110-150°C; 1H-NMR (300 MHz,CDCl3 + CD3OD): δ = 7.10 (m, 4H-aryl), 7.01 (d, J = 3.9,
1H-thiophene), 6.89 (d, J = 3.6, 1H-thiophene), 4.84
(s, 2H-CH2).
13C-NMR (75 MHz CDCl3 + CD3OD): 14.6,
27.8, 127.3 (2C), 127.5 (2C)127. 9 (2C), 130.0, 135.9, 139.4,
140.2. EI/MS m/z (%): 299.0 [M+˙]; 301.0 [M+ (Br81) 49];
[M+-Me] = 284.0; [M+-SMe] = 251.0; [M+-Br, Me frag-
ments] = 219.0; [M+-CH2Br, thiophene fragments] = 109.1;
[M+-CH2Br, thiophene, SMe fragments] = 77.5. Anal.
Calcd. For C12H11BrS2: C, 48.16; H, 3.71. Found: C, 48.10;
H, 3.77%.
2-(bromomethyl)-5-(4-iodophenyl)thiophene (3g). Brown
solid, Mp: > 300°C; 1H-NMR (300 MHz, CDCl3 + CD3OD):
δ = 7.76 (d, J = 2.1 Hz, 2H-Aryl), 7.58 (d, J = 1.8 Hz, 2H-
aryl), 7.18 (d, J = 4.2 Hz, 1H-Thiophene), 6.82 (d, J = 3.3 Hz,
1H-Thiophene), 4.62 (s, 2H-CH2).
13C-NMR (75 MHz
CDCl3 + CD3OD): 27.5, 94.6, 127.5 (2C), 129.0 (2C), 132.0,
135.7, 138.1 (2C), 140.0. EI/MS m/z (%): 378.1 [M+˙];
380.0 [M+ (Br81) 49]; [M+-I] = 252.9; [M+-aryl, I] = 177.0;
[M+-thiophene, aryl, I] = 95.8. Anal. Calcd. For C11H8BrIS:
C, 34.85; H, 2.13. Found: C, 34.80; H, 2.11%.
2-(bromomethyl)-5-p-tolylthiophene (3h). Brown gummy
matter;1H-NMR (300 MHz, CDCl3 + CD3OD): δ = 7.55-
7.40 (m, 4H-aryl, 2H-thiophene), 4.68 (s, 2H), 2.35 (S, 3H-
Me). 13C-NMR (75 MHz CDCl3 + CD3OD): 21.0, 28.1,
125.5 (2C), 127.5 (2C), 129.6 (2C), 130.5, 131.8, 136.5,
139.6. EI/MS m/z (%): 266.9 [M+˙]; 268.9 [M+ (Br81) 49];
[M+-CH2Br] = 175.0; [M
+-CH2Br, Me fragments] = 161.0;
[M+-CH2Br, thiophene fragments] = 91.0; [M
+-CH2Br,
aryl, Me fragments] = 83.4. Anal. Calcd. For C12H11BrS: C,
35.94; H, 4.15. Found: C, 35.84; H, 4.25%.
2-(bromomethyl)-5-(3,5-dimethylphenyl)thiophene (3i).
Brown liquid; 1H-NMR (300 MHz, CDCl3 + CD3OD): δ =
7.24 (s, 1H-aryl), 7.14 (d, J = 9.9, 2H-aryl), 7.11 (d, J =
10.5 Hz, 1H-thiophene), 6.95 (s, 1H-thiophene), 4.97
(s, 2H-CH2); 2.35 (s, 6H-2Me).
13C-NMR (75 MHz CDCl3 +
CD3OD): 21.8 (2C), 27.6, 127.4 (3C), 127.8, 130.8, 133.6,
135.9, 138.6 (2C), 139.8. EI/MS m/z (%): 280.2 [M+˙];
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189.0; [M+-CH2Br, aryl, 2Me] = 83.2; [M
+-CH2Br, Me]
ˉ =
174.0. Anal. Calcd. For C13H13BrS: C, 55.52; H, 4.66.
Found: C, 55.58; H, 4.63%.
Cytotoxicity studies by haemolytic assay
The cytotoxicity of synthesized compounds 2 and 3a-i
was determined by examining the haemolytic activity of
human blood cells, following the previously reported
method [46]. In a typical experiment, approximately
3 mL freshly obtained heparinized human blood was
collected from the volunteers after consent and counsel-
ing. The blood samples were then centrifuged for 5 min at
1000 rpm, and the blood plasma was discarded and cells
were washed three times with 5 mL chilled (4°C) sterile
isotonic Phosphate-buffered saline (PBS) (pH 7.4). Eryth-
rocytes were maintained 108 cells per mL for each assay.
Approximately, 100 μL of each synthesized compound
was mixed with human blood cells (108 cells/mL) separ-
ately. Later on, the Samples were incubated for 35 min at
37°C and agitated after 10 min. Soon after incubation, the
samples were placed on ice for 5 min, followed by centri-
fuge for 5 min at 100 rpm. Supernatant 100 μL were taken
from each tube and diluted 10 times with chilled (4°C)
PBS. Triton X-100 (0.1% v/v) was taken as positive con-
trol and phosphate buffer saline (PBS) was taken as
negative control and pass through the same process.
The absorbance value was measured at 576 nm using
μQuant (Bioteck, USA). Finally, the % RBCs lysis for each
sample was calculated.
Antithrombolytic activity
The blood samples were collected from volunteers after
consent and counseling. Venous blood was pinched from
healthy human volunteers without a history of anti-
coagulant treatment. The 100 μL of blood was transmit-
ted to each of the previously weighed micro-centrifuge
tubes to form clots. Then the solution of synthesized
compounds 2 and 3a-i (100 μL) having concentration of
1 mg/mL was added to the tubes, and incubated at 37°C
for 45 minutes. Streptokinase was used as standard clot
lysis agent and water as negative control for this assay. Clot
lysis activity results were presented in percentage [47].
Conclusions
In conclusion, novel series of 2-(bromomethyl)-5-aryl-
thiophenes(3a–i) were synthesized, and the cytotoxicity
of the newly synthesized compounds (2, 3a-i) against the
human blood cells was investigated. Almost, all the tested
compounds revealed some haemolytic activity in the safe
range but in particular 3f and 3i exhibited highest lysis of
blood cells viz. 69.7 and 33.6 % respectively. The synthe-
sized compounds exhibited low to moderate antithrombo-
lytic activity against human blood clot. The compound 3iwas found more potent for clot lysis among all synthesized
compounds. We anticipate that the continued investiga-
tion in this field will provide new insights and promote
the progress towards the development of ideal thrombo-
lytic therapy, characterized by maximized stable coronary
arterial thrombolysis with minimal bleeding. The highly
toxic compounds are deemed to be potential antitumor
agents.
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